Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Shots:

• Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China
• SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China, Hong Kong, Macau, And Taiwan
• Alpha-synuclein directed therapies help to treat patients with Parkinson’s disease and related neurological disorders addressing the unmet medical need

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire